tbuckley/cabot-search huggingface dataset:
Resistance to Avapritinib in PDGFRA-Driven GIST Is Caused by Secondary Mutations in the PDGFRA Kinase Domain
Authors: Susanne Grunewald, Lillian R. Klug, Thomas Mühlenberg, Jonas Lategahn, Johanna Falkenhorst, Ajia Town, Christiane Ehrt, Eva Wardelmann, Wolfgang Hartmann, Hans-Ulrich Schildhaus, Juergen Treckmann, Jonathan A. Fletcher, Sascha Jung, Paul Czodrowski, Stephen Miller, Oleg Schmidt-Kittler, Daniel Rauh, Michael C. Heinrich, Sebastian Bauer
Journal: Cancer Discovery (2020)

Abstract Gastrointestinal stromal tumors (GIST) harboring activating mutations of PDGFRA respond to imatinib, with the notable exception of the most common mutation, D842V. Avapritinib is a novel, potent KIT/PDGFRA inhibitor with substantial clinical activity in patients with the D842V genotype. To date, only a minority of PDGFRA-mutant patients treated with avapritinib have developed secondary resistance. Tumor and plasma biopsies in 6 of 7 patients with PDGFRA primary mutations who progressed on avapritinib or imatinib had secondary resistance mutations within PDGFRA exons 13, 14, and 15 that interfere with avapritinib binding. Secondary PDGFRA mutations causing V658A, N659K, Y676C, and G680R substitutions were found in 2 or more patients each, representing recurrent mechanisms of PDGFRA GIST drug resistance. Notably, most PDGFRA-mutant GISTs refractory to avapritinib remain dependent on the PDGFRA oncogenic signal. Inhibitors that target PDGFRA protein stability or inhibition of PDGFRA-dependent signaling pathways may overcome avapritinib resistance. Significance: Here, we provide the first description of avapritinib resistance mechanisms in PDGFRA-mutant GIST. This article is highlighted in the In This Issue feature, p. 1
66P Preoperative predictors of long-term outcomes for resectable intrahepatic cholangiocarcinoma (iCCA): Is there a space for neoadjuvant?
Authors: M. Niger, M. Droz, C. Sposito, F. Nichetti, A. Ottini, M. Brambilla, M. Bini, S. Paleino, F. Pietrantonio, M. Di Bartolomeo, F.G.M. De Braud, V. Mazzaferro
Journal: Annals of Oncology (2020)
Inflammasome signaling in human placental trophoblasts regulates immune defense against <i>Listeria monocytogenes</i> infection
Authors: Christina Megli, Stefanie Morosky, Dhivyaa Rajasundaram, Carolyn B. Coyne
Journal: The Journal of Experimental Medicine (2020)

The human placenta is a dynamic organ that modulates physiological adaptations to pregnancy. To define the immunological signature of the human placenta, we performed unbiased profiling of secreted immune factors from human chorionic villi isolated from placentas at mid and late stages of pregnancy. We show that placental trophoblasts constitutively secrete the inflammasome-associated cytokines IL-1β and IL-18, which is blocked by NLRP3 inflammasome inhibitors and occurs without detectable gasdermin D cleavage. We further show that placenta-derived IL-1β primes monocytes for inflammasome induction to protect against Listeria monocytogenes infection. Last, we show that the human placenta responds to L. monocytogenes infection through additional inflammasome activation and that inhibition of this pathway sensitizes villi to infection. Our results thus identify the inflammasome as an important mechanism by which the human placenta regulates systemic and local immunity during pregnancy to defend against L. monocytogenes infection.
1671MO Provision of palliative care for patients with cancer and SARS-CoV-2 infection
Authors: G.B. Soosaipillai, A. Sureda, C. Maluquer Artigal, S. Benafif, N. Chopra, N. Harbeck, R. Wuerstlein, R. Mesia Nin, E. Felip, D. Ottaviani, M. Galazi, A.J.X. Lee, R. Salazar, R. Sharkey, R. Reyes, J. Evans, M.C. Carmona Garcia, J. Tabernero, A. Prat, D.J. Pinato
Journal: Annals of Oncology (2020)
LBA77 Anti-SARS-CoV-2 antibody response in patients with cancer and oncology healthcare workers: A multicenter, prospective study
Authors: A. Marra, D.G. Generali, P. Zagami, S. Gandini, V. Cervoni, S. Venturini, S. Morganti, R. Passerini, R. Orecchia, G. Curigliano
Journal: Annals of Oncology (2020)
1692P SARS-CoV-2 RNA testing in cancer patients treated at a Department of Medical Oncology in Vienna, Austria
Authors: A.S. Berghoff, M. Gansterer, A.C. Bathke, W. Trutschnig, P. Hungerländer, J.M. Berger, J. Kreminger, A. Starzer, R. Schmidt, W. Lamm, M. Raderer, A.D. Gottlieb, N.J. Mauser, M. Preusser
Journal: Annals of Oncology (2020)
Return to sport for North American professional sport leagues in the context of COVID-19
Authors: John P DiFiori, Gary Green, Willem Meeuwisse, Margot Putukian, Gary S Solomon, Allen Sills
Journal: British Journal of Sports Medicine (2020)

COVID-19 is a respiratory illness that can spread from person to person. A range of clinical scenarios exist, from an asymptomatic disease course to SARS and death. This document describes important considerations for 5 North American professional sports leagues (Major League Baseball, Major League Soccer, National Basketball Association, National Football League and National Hockey league) assessing when and how to resume phased operations, including practices and games. Sports should prioritise and promote the health and safety of athletes, team and operational staff, and other participants, and should not unduly increase those individuals’ relative health risk while contributing to economic recovery, providing entertainment for the public and leading a responsible restoration of civic life. Because elite professional sport ordinarily is conducted in a controlled environment, professional sports leagues may be able to achieve these goals. This document is focused on professional sports leagues in North America, and although many of the statements are generalisable to professional sporting settings throughout the world, other considerations may apply to sports in other countries.
1910P Outcomes of systemic therapy after first line therapy in patients (p) with malignant pleural mesothelioma (MPM)
Authors: S. Cedres, P. Iranzo, A. Callejo, N. Pardo, A. Navarro, A. Martinez-Marti, N. Saoudi Gonzalez, A. Valdivia, V. Monton, J. Gonzalo, A. Pedrola, R. Dienstmann, E. Felip
Journal: Annals of Oncology (2020)
586P Bidirectional chemotherapy for initially unresectable malignant peritoneal mesothelioma: Proof of concept of a new conversion strategy?
Authors: M. Gelli, I. Sourrouille, C. Smolenschi, P. Combari, A. Hollebecque, L. Benhaim, D. Peggy, M. Faron, D. Elias, D. Goere, H. Charles, V. Boige, D. Malka, M.P. Ducreux
Journal: Annals of Oncology (2020)
1837P Febrile neutropenia (FN) primary prophylaxis (1º Prlx) with platinum and etoposide (P&amp;E) chemotherapy (ChT) regimens: Some action needed
Authors: A.S. Spencer, A.F. Palma dos Reis, A. Parmanande, J.V. Barreira, D. Simão, M. Sardinha, J. Mendes, A. Machado, P.W. Pereira, R. Luz
Journal: Annals of Oncology (2020)
Proton Pump Inhibitors and Fractures During Growth—Reply
Authors: Yun-Han Wang, Björn Pasternak
Journal: JAMA Pediatrics (2020)

In Reply We greatly appreciate the comments from Sugiyama on our study1 evaluating the association between proton pump inhibitor (PPI) use and risk of fracture in children. We agree that the results need to be interpreted carefully and that additional research is needed.
984P Sorafenib plus hepatic arterial infusion chemotherapy versus sorafenib alone for advanced hepatocellular carcinoma with major portal vein tumor thrombosis (Vp3/4): A randomized phase II trial
Authors: X. Wang, K. Zheng, G. Cao, L. Xu, X. Zhu, H. Chen, S. Fu, D. Wu, R. Yang, K. Wang, W. Liu, Q. Bao, C. Hao, L. Shen, B. Xing
Journal: Annals of Oncology (2020)
91P Transcriptomic mapping of integrins and immune activation in Basal-like and HER2+ breast cancer
Authors: M. Baliu Piqué, K. Rojas, A. Manzano, C. Saiz Ladera, V. García Barberán, F.J. Cimas, P. Pérez Segura, A. Pandiella, B. Győrffy, A. Ocaña
Journal: Annals of Oncology (2020)
LBA3_PR An international randomized trial, comparing post-operative conformal radiotherapy (PORT) to no PORT, in patients with completely resected non-small cell lung cancer (NSCLC) and mediastinal N2 involvement: Primary end-point analysis of LungART (IFCT-0503, UK NCRI, SAKK) NCT00410683
Authors: C. Le Pechoux, N. Pourel, F. Barlesi, C. Faivre-Finn, D. Lerouge, G. Zalcman, D. Antoni, B. Lamezec, U. Nestle, P. Boisselier, F. Thillays, A. Paumier, E. Dansin, K. Peignaux, J. Madelaine, E. Pichon, A. Larrouy, O. Riesterer, A. Lavole, A. Bardet
Journal: Annals of Oncology (2020)
624P Tolerability of olaparib (OLA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations: PROfound
Authors: G. Roubaud, M. Ozguroglu, N. Penel, N. Matsubara, N. Mehra, M.P. Kolinsky, G. Procopio, S. Feyerabend, J.Y. Joung, G. Gravis, K. Nishimura, C. Gedye, C. Padua, N. Shore, A. Thiery-Vuillemin, C. Gresty, N. Brickel, J. Burgents, A. Allen, K. Fizazi
Journal: Annals of Oncology (2020)
The COVID-19 pandemic and colorectal cancer prevention: God tempers the wind to the shorn lamb
Authors: Maria Pellisé
Journal: Endoscopy (2020)

The benefits of colorectal cancer (CRC) screening programs, in terms of cancer incidence and mortality, are indisputable. The medicalization of a large segment of the healthy and asymptomatic population is now well accepted as an investment to prevent future health harms and costs in the small proportion of individuals that could otherwise develop cancer. Indeed, CRC prevention has instigated a major shift in endoscopy practice. However, it has also generated an overwhelming workload for endoscopy units, which suffer from a limited and rigid capacity.
Next generation sequencing pitfalls in diagnosing trypsinogen (PRSS1) mutations in chronic pancreatitis
Authors: Frank U Weiss, Felix Laemmerhirt, Markus M Lerch
Journal: Gut (2020)

With interest we read the recent study by Hegyi et al ,1 who established that the risk for developing pancreatitis conferred by a haplotype spanning the trypsin locus (PRSS1–PRSS22 3) is strongly dependent on exogenous factors. Changes in PRSS14 or PRSS25 have long been reported to associate with either an increased or a decreased pancreatitis risk, depending on how they contribute to the activation/degradation balance within pancreatic acinar cells. Other germline changes in proteins outside the protease cascade induce pancreatic injury by interfering with intracellular protein processing6 or induction of endoplasmic reticulum stress.7

All recent guidelines agree that mutations affecting the trypsin locus confer the highest risk of developing pancreatitis and put trypsin (PRSS1) in the first line of testing in patients with suspected hereditary pancreatitis (HP).8 Challenges arising from testing these patients include not only the more than 80 known PRSS1 variants of sometimes uncertain clinical relevance (http://www.pancreasgenetics.org/), but also the progression of diagnostic technology towards next generation sequencing (NGS)—especially in conjunction with consumer genetics offered to the general …
1298P RELAY, ramucirumab plus erlotinib (RAM+ERL) versus placebo plus erlotinib (P+ERL) in untreated EGFR mutated metastatic non-small cell lung cancer (NSCLC): Exposure-response relationship
Authors: K. Nakagawa, E. Garon, L. Gao, S. Callies, A. Zimmermann, R. Walgren, C. Visseren-Grul, M. Reck
Journal: Annals of Oncology (2020)
1075TiP MEDI1191, a novel IL-12 mRNA therapy for intratumoral (IT) injection for advanced solid tumours
Authors: T. Marron, V. Subbiah, O. Hamid, S. Goel, M.D. Hellmann, B.A. Carneiro, S.P. Pate, E. de Vries, N. Luheshi, O. Hamid, A. Gascó Hernández
Journal: Annals of Oncology (2020)
758P Assessment of prognostic and predictive value of FGFR alterations (FGFRa) in a real-world cohort of patients (pts) with high-risk pT1 non-muscle-invasive bladder cancer (NMIBC)
Authors: J. Breyer, M. Monga, R. Mayr, W. Otto, M. Burger, M. Eckstein, R. Stöhr, P. Erben, C. Bolenz, S. Eidt, R. Sundaram, M. Baig, A. Galluzzi, R. Wirtz, A. Hartmann, A. Santiago-Walker
Journal: Annals of Oncology (2020)
863P A phase I study of mirvetuximab soravtansine (MIRV) and gemcitabine (G) in pts with selected FRα -positive solid tumours: Results in the endometrial cancer (EC) cohort
Authors: M.C. Cristea, P. Frankel, T. Synold, D.B. Stewart, E. Wang, A. Jung, S. Wilczynski, M. Tran, G.E. Konecny, M. Eng, L. Kilpatrick, Y-J. Chen, S. Glaser, E. Han, T. Dellinger, A. Hakim, S. Lee, R.J. Morgan, L. Rodriguez, M. Wakabayashi
Journal: Annals of Oncology (2020)
815MO The impact of chemosensitivity assessed by modeled CA-125 KELIM on the likelihood of long progression-free survivorship (PS) after 1st line treatment in ovarian cancer: An analysis of 4,450 patients
Authors: B. You, L. Van Wagensveld, M. Tod, G.S. Sonke, R. Kruitwagen, A. du Bois, F. Selle, T.J. Perren, J. Pfisterer, F. Joly, A. Cook, M-C. Kaminsky-Forrett, K. Wollschlaeger, A. Lortholary, O. Tome, A. Leary, G. Freyer, M. Van Der AA, O. Colomban
Journal: Annals of Oncology (2020)
Large-Scale Functional Brain Network Architecture Changes Associated With Trauma-Related Dissociation
Authors: Lauren A.M. Lebois, Meiling Li, Justin T. Baker, Jonathan D. Wolff, Danhong Wang, Ashley M. Lambros, Elizabeth Grinspoon, Sherry Winternitz, Jianxun Ren, Atilla Gönenç, Staci A. Gruber, Kerry J. Ressler, Hesheng Liu, Milissa L. Kaufman
Journal: American Journal of Psychiatry (2020)

Dissociative experiences commonly occur in response to trauma, and while their presence strongly affects treatment approaches in posttraumatic spectrum disorders, their etiology remains poorly understood and their phenomenology incompletely characterized. Methods to reliably assess the severity of dissociation symptoms, without relying solely on self-report, would have tremendous clinical utility. Brain-based measures have the potential to augment symptom reports, although it remains unclear whether brain-based measures of dissociation are sufficiently sensitive and robust to enable individual-level estimation of dissociation severity based on brain function. The authors sought to test the robustness and sensitivity of a brain-based measure of dissociation severity.
918MO Molecular enrichment and outcomes based on ESCAT levels in metastatic salivary gland tumours (mSGT) patients (pts) treated in early clinical trials
Authors: A. Hernando-Calvo, M.A. Rezqallah Aron, A.B. Azaro Pedrazzoli, M. Vieito, O. Saavedra Santa Gadea, S. Aguilar, V. Galvão, R. Berché, G. Alonso Casal, C. Bescós, A. De Pablo, J. Lorente, J. Giralt, S. Benavente, J. Temprana-Salvador, M. Alberola, R. Dienstmann, E. Felip, E. Garralda, I. Braña
Journal: Annals of Oncology (2020)
1925P DNA methylation signature for prediction of metastasis and response to multikinase inhibitors of differentiated thyroid carcinoma (DTC)
Authors: J. Hernando, C. Zafon, A. Diez-Villanueva, C. Iglesias, H. Rodriguez, N. Villalmazo, J. Gil, E. Klein-Hesselink, M. Roca, H. Verdaguer, D.A. Acosta Eyzaguirre, M. Diez Garcia, E. Lindo, J. Hernandez-Losa, J. Reverter, M. Puig-Domingo, T. Links, J. Capdevila, M. Jordà
Journal: Annals of Oncology (2020)
Muse cell spheroids have therapeutic effect on corneal scarring wound in mice and tree shrews
Authors: Yonglong Guo, Yunxia Xue, Peiyuan Wang, Zekai Cui, Jixing Cao, Shiwei Liu, Quan Yu, Qiaolang Zeng, Deliang Zhu, Mengyuan Xie, Jun Zhang, Zhijie Li, Hongwei Liu, Jingxiang Zhong, Jiansu Chen
Journal: Science Translational Medicine (2020)

Corneal stromal cells differentiated from Muse spheroids had therapeutic effects on wounded corneas in mice and tree shrews.
575P TLD-1, a novel liposomal doxorubicin, in patients (pts) with advanced solid tumours: Dose escalation part of a multicenter open-label phase I trial (SAKK 65/16)
Authors: D. Hess, I. Colombo, S. Haefliger, S. Bastian, M. Rabaglio, Y. Metaxas, K. Eckhardt, C. Kopp, S. Hayoz, A. Mueller-Schoell, C. Kloft, C. Sessa, A. Stathis, M. Joerger
Journal: Annals of Oncology (2020)
Designing Hypoxia‐Responsive Nanotheranostic Agents for Tumor Imaging and Therapy
Authors: Huige Zhou, Fenglan Qin, Chunying Chen
Journal: Advanced Healthcare Materials (2020)

Abstract Hypoxia, a common feature of most solid tumors, plays an important role in tumor proliferation, metastasis, and invasion, leading to drug, radiation, and photodynamic therapy resistance, and resulting in a sharp reduction in the disease‐free survival rate of tumor patients. The lack of sufficient blood supply to the interior regions of tumors hinders the delivery of traditional drugs and contrast agents, interfering with their accumulation in the hypoxic region, and preventing efficient theranostics. Thus, there is a need for the fabrication of novel tumor theranostic agents that overcome these obstacles. Reports, in recent years, of hypoxia‐responsive nanomaterials may provide with such means. In this review, a comprehensive description of the physicochemical and biological characteristics of hypoxic tumor tissues is provided, the principles of designing the hypoxia‐responsive tumor theranostic agents are discussed, and the recent research into hypoxia‐triggered nanomaterials is examined. Additionally, other hypoxia‐associated responsive strategies, the current limitations, and future prospects for hypoxia‐responsive nanotheranostic agents in tumor treatment are discussed.
113P C-reactive protein (CRP) levels in immune checkpoint inhibitor response and progression in advanced non-small cell lung cancer: A bi-center study
Authors: F. Posch, D. Barth, W.M. Brueckl, G. Zeitler, V. Foris, S. Mollnar, M. Stotz, C.H. Rossmann, A. Terbuch, M. Balic, T. Niedrist, T. Bertsch, H. Stöger, M. Pichler, H. Olschewski, G. Absenger, J.H. Ficker, A. Gerger, J.M. Riedl
Journal: Annals of Oncology (2020)
1341P Afatinib in Asian and non-Asian patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC harboring uncommon mutations
Authors: J.C-H. Yang, M. Schuler, S. Popat, S. Miura, S. Heeke, A. Passaro, F. de Marinis, K. Park, E.S. Kim
Journal: Annals of Oncology (2020)
858P Patient-reported outcomes (PROs) in the GARNET trial in patients (pts) with advanced or recurrent mismatch repair deficient/microsatelite instability-high (dMMR/MSI-H) endometrial cancer (EC) treated with dostarlimab
Authors: R. Kristeleit, C. Matthews, A. Redondo, J. Huang, L. Eliason, E. Im, J. Brown
Journal: Annals of Oncology (2020)
Physiologic and Clinical Features of the Paralympic Athlete’s Heart
Authors: Antonio Pelliccia, Filippo Maria Quattrini, Elena Cavarretta, Maria Rosaria Squeo, Paolo Emilio Adami, Fernando Maria Di Paolo, Antonio Spataro, Marco Bernardi
Journal: JAMA Cardiology (2020)

Paralympic medicine is a newly adopted term to describe the varied health care issues associated with athletes in the Paralympics. Scarce scientific data, however, are currently available describing the cardiac remodeling in Paralympic athletes.To investigate the physiological and clinical characteristics of the Paralympic athlete's heart and derive the normative values.This is a single-center study on a relatively large cohort of Paralympic athletes, conducted at the Italian Institute of Sport Medicine and Science. Paralympic athletes free of cardiac or systemic pathologic conditions other than their cause of disability were selected for participation in the Paralympic Games from January 2000 to June 2014. Athletes were arbitrarily classified for disability in 2 groups: those with spinal cord injuries (SCI) and those with non-SCI (NSCI). Data analysis occurred from March 2019 to June 2020.The primary outcome was the difference in cardiac remodeling in Paralympic athletes according to disability type and sports discipline type. Athletes underwent cardiac evaluation, including 12-lead and exercise electrocardiograms, echocardiography, and cardiopulmonary exercise testing.Among 252 consecutive Paralympic athletes (median [interquartile range (IQR)] age, 34 [29-41] years; 188 men [74.6%]), 110 had SCI and 142 had NSCI. Those with SCI showed a higher prevalence of abnormal electrocardiogram findings than those with NSCI (13 of 110 [11.8%] vs 6 of 142 [4.2%]; P = .003), smaller left ventricular end-diastolic dimension (median [IQR], 48 [46-52] vs 51 [48-54] mm; P = .001) and left ventricular mass index (median [IQR], 80.6 [69-94] vs 91.3 [80-108] g/m2; P = .001), and lower peak oxygen uptake (VO2) (median [IQR], 27.1 [2-34] vs 38.5 [30-47] mL/min/kg; P = .001) in comparison with those with NSCI. Regarding sport discipline, endurance athletes had a larger left ventricular cavity (median [IQR], 52 [47-54] vs 49 [47-53] mm; P = .006) and higher peak VO2 (median [IQR], 46 [39-55] vs 30 [25-35] mL/min/kg; P = .001) than athletes in nonendurance sports.Cardiac remodeling in Paralympic athletes differed by disability and sport discipline. Having NSCI lesions and engaging in endurance sports were associated with the largest left ventricular cavity and left ventricular mass and highest VO2 peak. Having SCI lesions and engaging in nonendurance disciplines, on the contrary, were associated with the smallest left ventricular cavity and mass and lowest VO2 peak.
1143P Nivolumab and ipilimumab (N+I) is active in patients (pts) with metastatic uveal melanoma (mUM) with extra-hepatic only involvement: Pooled analysis from 2 phase II trials
Authors: J.M. Piulats Rodriguez, S. Patel, E. Espinosa, M.S. Pelster, L. de la Cruz Merino, L.T. Khoja, A.M. Joshua, C. Tebe, A. Berrocal
Journal: Annals of Oncology (2020)
1985P The correlation between the amount of surface receptors TIM-3 and PD-1 and cytotoxic activity in patients with breast cancer
Authors: M.S. Kuznetsova, J.N. Khantakova, V.P. Tereschenko, A.A. Khristin, J.A. Shevchenko, S.V. Sidorov, S.V. Sennikov
Journal: Annals of Oncology (2020)
1349P Lorlatinib for advanced ROS1+ non-small cell lung cancer (NSCLC): Efficacy and safety data from IFCT-1803 LORLATU expanded access program (EAP) cohort
Authors: N. Girard, S. Galland Girodet, M. Duruisseaux, V. Avrillon, B. Roch, J. Otto, J. Cadranel, M. Coudurier, D. Moro-Sibilot, T. Egenod, R. Lamy, J. Bennouna, G. Zalcman, C. Ricordel, J. Tillon, L. Odier, B. Besse, P. Missy, V. Westeel, S. Baldacci
Journal: Annals of Oncology (2020)
It’s Time to Put Children and Young People First During the Global COVID-19 Pandemic
Authors: Saul N. Faust, Alasdair P. S. Munro
Journal: JAMA Pediatrics (2020)

Russell M. Viner, PhD; Oliver T. Mytton, PhD; Chris Bonell, PhD; G. J. Melendez-Torres, PhD; Joseph Ward, MBBS; Lee Hudson, PhD; Claire Waddington, DPhil; James Thomas, PhD; Simon Russell, PhD; Fiona van der Klis, PhD; Archana Koirala, MBChB; Shamez Ladhani, MD; Jasmina Panovska-Griffiths, DPhil; Nicholas G. Davies, DPhil; Robert Booy, MD; Rosalind M. Eggo, PhD
132P TRKing PTC patients: NTRK gene fusion frequency and clinical characteristics of a Finnish papillary thyroid cancer cohort
Authors: W. Zhang, R. Schulze-Rath, B. Farahmand, S. Bender, A. Schmitz, M. Tukiainen, M. Perälä, J. Zong
Journal: Annals of Oncology (2020)
GMC should rethink the way it accuses doctors of sexual motivation during intimate examinations, says judge
Authors: Clare Dyer
Journal: BMJ (2020)

A High Court judge has suggested that the General Medical Council should rethink the way it formulates charges against doctors it accuses of having a sexual motivation in carrying out intimate examinations on patients.1

Mrs Justice Foster made her comments when allowing the GMC’s appeal against a finding by a medical practitioners tribunal that two intimate examinations by a GP were not sexually motivated.

She suggested that the usual form of GMC charge in such cases, setting out what the doctor is alleged to have done, and then alleging in a further charge that the motivation was sexual, might have overcomplicated the task for the tribunal. She proposed that, although the context was different, the GMC should look at what constitutes a sexual …
220P Annotating MammaPrint and BluePrint gene profile to the Hallmarks of cancer and understanding the biology of MammaPrint extreme risk groups
Authors: J.C. Haan, R. Bhaskaran, L. Mittempergher, E. Lujinovic, W. Audeh, F. Penault-Llorca, A. Glas
Journal: Annals of Oncology (2020)